Proneuron is the first company to harness the power of the body's own immune system for the treatment of neurological disorders, which until now were considered incurable
Company
Proneuron Biotechnologies is enrolling patients suffering from complete spinal cord injuries to participate in a Phase II multi-center clinical study. Patients within 14 days of injury will be implanted with ProCord. Proneuron Biotechnologies, a Delaware company, is in advanced stages of clinical development in a number of attractive neurological markets. Proneuron is the first company to harness the power of the body's own immune system for the treatment of debilitating central nervous system (CNS) disorders. The concept of helping the body to "cure" itself, offers hope to the millions of victims of nervous system-related disorders. Proneuron Biotechnologies is developing therapies for neurological disorders, including spinal cord injury (SCI), other central nervous system trauma and back injuries. Our products are based on proprietary technology for modulating the interaction between the nervous system and the immune system. Proneuron is enrolling a total of 61 patients suffering from complete spinal cord injuries in a Phase II multi-center clinical study. Patients will be implanted with ProCord. Study sites must be informed of a candidate patient within a few days of the spinal cord injury to allow time to complete the necessary tests and procedures within 14 days of injury.
Home Page
   Company
 
      Technology
 
       Therapies
 
       Clinical Studies
 
      News & Events
 
     Links
 
   Careers
 

COMPANY - COLLABORATIONS


Academic Collaborations

Proneuron benefits from its exclusive research agreement with the Weizmann Institute of Science, Israel (www.weizmann.ac.il). Under the terms of this agreement, initiated in 1996, 15 scientists support Proneuron's pipeline expansion under the leadership of Prof. Michal Schwartz.


  

Goverment Collaborations

Proneuron is currently leading a project funded by the United States Department of Defenseís research agency, Defense Advanced Research Projects Agency (DARPA) (www.darpa.mil).  The project involves the investigation of the therapeutic potency of Proneuronís proprietary molecule, PN277, to reduce functional damage following exposure to nerve gas toxicity.  The collaboration began in 2009 with a three year grant approved by DARPA for research in Israel and at the United States Army Medical Research Institute of Chemical Defense (USAMRICD) (chemdef.apgea.army.mil) labs in the United States. 

Nerve gas intoxication is a major threat in the battlefield as well as to civilians in terrorist attacks. In a preliminary study using rats, PBI has demonstrated the potential of PN277 in attenuating sarin induced brain damage. PBIís goal is to continue to develop PN277 for this indication with the support of DARPA


 

Pharmaceutical Alliances

Since October 2001, Proneuron has been collaborating with Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA. www.tevapharm.com) in the development of Proneuron's proprietary therapeutic vaccine for various acute and chronic neurodegenerative disorders. The vaccine uses Copolymer-1 (Cop-1), the active compound in Copaxoneô (Teva Pharmaceutical Industries Ltd.), which is an approved treatment for Multiple Sclerosis.


Clinical Sites

Proneuron places great importance on collaborating with centers of excellence in the field of spinal cord injuries. Proneuron was engaged in active projects with several centers in Israel, the U.S. and Europe.

Erasme Hospital, Belgium (http://hopitalerasme.org/)                                                        In Europe, Proneuron collaborates with the Erasme Hospital in Brussels, Belgium. A Phase Ib clinical study took place  at this well-respected medical facility, affiliated with the Universite Libre de Bruxelles. Prof. Jacques Brotchi, Professor and Chairman of the Neurosurgery Service at the Erasme Hospital and an eminent spinal cord neurosurgeon is led the study.

Sheba Medical Center, Tel Hashomer, Israel                                                                Following the successful collaboration in performing Proneuronís Phase I clinical study of ProCord, Sheba was the first center worldwide to participate in the ProCordís Phase II study. 
 
Craig Hospital, Denver, Colorado, U.S. (www.craighospital.org)                                                    Craig Hospital is exclusively dedicated to the specialty rehabilitation and research for patients with spinal cord injury and traumatic brain injury and has treated more than 24,000 patients since 1956 - more spinal cord injury patients than any other single facility in the world. Craig has been rated every year in the Top Ten Rehabilitation Hospitals by US News and World Report since the ratings began fourteen years ago. In 2002, patients came to Craig from all 50 states and several foreign countries to take advantage of its expertise, experience, and caring environment. Proneuron's collaboration with Craig was recognized by the BIRD Foundation which granted $1 million towards the establishment of a Proneuron's cell processing center within the grounds of Craig and the execution of clinical trials for ProCord.      

Kessler Institute for Rehabilitation, West Orange, New Jersey, U.S. (www.kessler-rehab.com) Kessler, one of the nation's leading providers of comprehensive physical medicine and rehabilitation services, has been addressing the needs of individuals with disabilities and their families for more than fifty years. In that time, Kessler Rehabilitation Corporation has grown from a 16-bed hospital in suburban New Jersey to a unique network of rehabilitation services.    

The University Hospital , Newark, New Jersey, U.S.A.(www.theuniversityhospital.com)
As the principal teaching hospital of the University of Dentistry and Medicine of New Jersey Medical School (www.umdnj.edu) , The University Hospital is New Jersey's busiest trauma center, and the center of referral for many of the stateís most advanced medical services and specialty care programs .                                       

The Mount Sinai Medical Center, New York City, New York, U.S. (www.mountsinaihospital.org) Founded in 1852, The Mount Sinai Hospital is one of the country's oldest and largest voluntary teaching hospitals. Mount Sinai is internationally acclaimed for excellence in clinical care, education, and scientific research in nearly every aspect of medicine. Mount Sinai's 1,171-bed tertiary-care teaching hospital with a medical staff of nearly 1,800 provides physicians who deliver the most advanced and compassionate inpatient and outpatient care.                                                                                                                      

Shepherd Center, Atlanta, GA.(www.shepherd.org)
Shepherd Center is an Atlanta-based catastrophic care hospital, treating people with spinal cord injuries, acquired brain injuries, multiple sclerosis and other neuromuscular illnesses and urological problems.

Shriners Hospital or Children, Philadelphia (www.shrinershq.org/shc/philadelphia/)
The Shriners Hospital in Philadelphia is a 59-bed pediatric orthopaedic hospital providing a complete range of specialized medical and rehabilitation services at no charge to children with orthopaedic problems or spinal cord injuries. The hospital is one of 22 Shriners Hospitals throughout North America.





Cell Processing

Progenitor Cell Therapy, L.L.C., USA (www.progenitorcelltherapy.com).
Progenitor Cell Therapy, L.L.C. (PCT) is a commercial cell engineering company that provides for the collection, manufacturing, storage and redistribution of human cells for therapeutic purposes through a nationwide network, operated in compliance with current Good Manufacturing Practices. The PCT facility manufactured ProCord for Proneuron's clinical trials in New York and New Jersey.

Cell Dynamics, L.L.C. , USA (www.celldynamicsllc.com)
Cell Dynamics is a cGMP tissue processing laboratory dedicated to the processing of human tissues and cells for research, transplant and cell-derived therapeutics. The company currently specializes in procuring and processing tissues from neonate donors, but utilizes cells from human donors of all ages. Cell Dynamics will manufactured ProCord for Proneuron's clinical trials in Atlanta, GA
 
Disclaimer | Site Map | Home Page| Contact Us Top of page Print this page
 

Proneuron Biotechnologies is engaged in research
related to spinal cord injuries and paralysis cure.



















Our friends on the web
Judaica Shop
Spinal Cord Injury
Virtual Keyboard
Spinal Cord Injuries
Flowers Israel
Mobile NoteTaker
Marine Construction
Australia Flowers
Rugged Computers
Mobile Phone Disabler
Digital Pen